Gene study could personalize asthma inhalers for kids
NCT ID NCT03592212
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a variation in the PDE4 gene influences how well children with persistent asthma respond to the common rescue inhaler salbutamol. Researchers measured lung function before and after giving the drug and compared results across different gene types. The study was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Salbutamol
- What this could lead to
- If successful, this could help personalize asthma treatment by identifying which children are more likely to benefit from salbutamol based on their genes.
- What could go wrong
- This was a small, terminated study with only 99 participants, so results may be limited and not apply to all children with asthma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker -Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?